Skip to content

Study · Not a test of the peptide alone · 2026

2 results

Effect of the COVID-19 Pandemic on Treatment Strategies for Secondary Prevention of Hip Fragility Fractures.

Mazza O, Abu-Leil M, Cohen I, Weiss CS, Haim A

The Israel Medical Association journal : IMAJ1 Jan 2026

PMID42298929 (opens in a new tab)PepBankPUB-42298929
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 01HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    In patients with hip fractures, pooled osteoporosis treatment including abaloparatide decreased from 40.4% in 2019 to 33.5% in 2021.

    In plain wordsIn patients with hip fractures, pooled osteoporosis treatment including abaloparatide decreased from 40.4% in 2019 to 33.5% in 2021.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseOsteoporosis treatment frequency
    Study

    n: not reported in source

    Comparator
    2019
    Outcome group
    Patterns of use · Musculoskeletal

    Measurements

    Treatment frequency
    40.4%
    2019
    Treatment frequency
    33.5%
    2021

    Source sentences

    Summary
    Treatment frequency decreased over time, with rates declining from 40.4% in 2019 to 33.5% in 2021 (P-value < 0.05).
    3 context sentences
    Summary · context
    This retrospective diagnostic cohort study used automated electronic medical records database from Clalit Health Services.
    Summary · context
    Data regarding patients with hip fractures from January 2017 through September 2021 were extracted from the database.
    Summary · context
    Treatment for osteoporosis included one of the following treatments: alendronate, risedronate, zoledronate, abaloparatide, denosumab, romosozumab, and teriparatide.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

  2. 02HumanNot a test of Abaloparatide (Tymlos) aloneObservational studyOther

    In patients with hip fractures, prompt care management within 3 months, covering pooled osteoporosis treatments including abaloparatide, increased from 47.3% in 2020 and 48.7% in 2019 to 62.5% in 2021.

    In plain wordsIn patients with hip fractures, prompt pooled treatment including abaloparatide rose from 47.3% in 2020 and 48.7% in 2019 to 62.5% in 2021.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreasePrompt care management within 3 months, 2021 versus 2019 and 2020
    Study

    n: not reported in source

    Comparator
    2019 and 2020
    Outcome group
    Patterns of use · Musculoskeletal

    Measurements

    Prompt care within 3 months
    47.3%
    2020
    Prompt care within 3 months
    48.7%
    2019
    Prompt care within 3 months
    62.5%
    2021

    Source sentences

    Summary
    However, the percentage of prompt care management (within 3 months) increased between 2020 and 2021 (47.3%-62.5%) and between 2019 and 2021 (48.7%-62.5%), P < 0.05.
    4 context sentences
    Summary · context
    This retrospective diagnostic cohort study used automated electronic medical records database from Clalit Health Services.
    Summary · context
    Data regarding patients with hip fractures from January 2017 through September 2021 were extracted from the database.
    Summary · context
    Treatment for osteoporosis included one of the following treatments: alendronate, risedronate, zoledronate, abaloparatide, denosumab, romosozumab, and teriparatide.
    Summary · context
    The primary outcome variable in the study is the time taken to initiate appropriate therapy for the secondary prevention of femoral neck fractures.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.